Abstracts tagged "rheumatoid arthritis"

Abstract Number: L09 • ACR Convergence 2023
Efficacy and Safety of LNK01001 in Chinese Patients with Moderate to Severe Active Rheumatoid Arthritis with an Inadequate Response to Conventional Synthetic DMARDs: 24-week Results from a Phase 2 Trial
Chanyuan Wu¹, Xuebin Wang², Jiankang Hu³, Xiaofei Shi⁴, Xiaoxia Wang⁵, Xuan Zhang⁶, Ju Liu⁷, Hui Rao⁸, Jianhong Zhao⁹, Rong Du¹⁰, Zhenyu Jiang¹¹, Huaxiang liu¹², Lin Liu¹³, Shengyun Liu¹⁴, Changhao Xie¹⁵, Xiangping Liao¹⁶, Lie Dai¹⁷, Zhiduo Hou¹⁸, Jingchun Jin¹⁹, Tianwang Li²⁰, Deqian Meng²¹, Yongfu Wang²², Jian Wu²³, Jieruo Gu²⁴, Wei Wei²⁵, Yu Zhuang²⁶, Kuanting Wang²⁷, Rong Zhang²⁸, Xiao Zhang²⁹, Huaping Wei³⁰, Zhao-Kui Wan³¹, Jun Wang³¹, Michael Vazquez³², Henry Wu³³ and Xiaofeng Zeng¹, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Binzhou Medical University Hospital, Binzhou, China, ³Pingxiang People's Hospital, Pingxiang, China, ⁴The 1st Affiliated Hospital of He'nan University, Luoyang, China, ⁵Second Hospital of Shanxi Medical University, Taiyuan, China, ⁶Beijing Hospital, Beijing, China, ⁷Jiujiang No. 1 People's Hospital, Jiujiang, China, ⁸Hunan Provincial People's Hospital, Changsha, China, ⁹Jining First People's Hospital, Jining, China, ¹⁰Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹¹First Affiliated Hospital of Jilin University, Changchun, China, ¹²Qilu Hospital of Shandong University, Jinan, China, ¹³Central Hospital of Xuzhou City, Xuzhou, China, ¹⁴The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, ¹⁵The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, ¹⁶Chenzhou First People's Hospital, Binzhou, China, ¹⁷Sun Yat-Sen Memorial Hospital, Guangzhou, China, ¹⁸Shantou University Medical College No.1 Affiliated Hospital, Shantou, China, ¹⁹Yanbian University Affiliated Hospital, Yanbian, China, ²⁰guangdong second provincial general hospital, Guangzhou, China, ²¹Huai'an First People's Hospital, Huaian, China, ²²The First Affiliated Hospital of Baotou Medical College, Baotou, China, ²³The First Affiliated Hospital of Soochow University, Suzhou, China, ²⁴The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ²⁵Tianjin Medical University General Hospital, Tianjin, China, ²⁶Huizhou Central People's Hospital, Huizhou, China, ²⁷Peking University Shougang Hospital, Beijing, China, ²⁸The First Hospital of China Medial University, Shenyang, China, ²⁹Guangdong Provincial People's Hospital, Guangzhou, China, ³⁰Lynk Pharmaceuticals Co., Ltd., Hangzhou, China, ³¹Lynk Pharma, Hangzhou, China, ³²Lynk Pharma, Saint Louis, MO, ³³Lynk Pharma, Nanjing, China
Background/Purpose: LNK01001 is a selective oral JAK1 inhibitor in clinical development for treating autoimmune and inflammatory diseases, including rheumatoid arthritis (RA). Here, we report the…
Abstract Number: L20 • ACR Convergence 2023
Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study
Li Wang¹, Dong Xu², Jianmin Fang³, Qing Zuraw⁴ and Fengchun Zhang¹, ¹Peking Union Medical College Hospital, Beijing, China, ²Peking Union Medical College Hospital, Dong Cheng District, China, ³RemeGen Co, Ltd., Yantai, China, ⁴RemeGen Biosciences, Inc., San Francisco, CA
Background/Purpose: Telitacicept is a recombinant fusion protein targeting and neutralizing BLyS and APRIL. This phase 3, randomized, double-blind study evaluated the efficacy and safety of…
Abstract Number: 0041 • ACR Convergence 2023
Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment
Jia Li, Yanrong Cai, Xin Guan, Meike Ewald, Lars-Oliver Tykocinski, Hanns-Martin Lorenz and Theresa Tretter, Department of Internal Medicine V, Div. of Rheumatology, University Hospital Heidelberg, Heidelberg, Germany
Background/Purpose: Activated macrophages (Mph) can be subdivided in at least 2 major subgroups according to their polarization into classical pro-(M1-Mph) or anti-inflammatory (M2-Mph) subtypes. Together…
Abstract Number: 0121 • ACR Convergence 2023
High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Jeong Yee¹, Candace Feldman¹, Emily G. Oakes¹, Elizabeth Karlson¹, Jack Ellrodt¹, Laura Kubzansky², Karestan Koenen² and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard T.H. Chan School of Public Health, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are complex autoimmune diseases associated with pain and decreased quality of life. Mental health conditions related…
Abstract Number: 0266 • ACR Convergence 2023
E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases
Verónica Pulito-Cueto¹, Sara Remuzgo-Martinez², Fernanda Genre Romero², Belén Atienza-Mateo³, Victor Mora-Cuesta⁴, David Iturbe-Fernández⁴, Leticia Lera-Gómez⁵, María Sebastián-Mora¹, Virginia Portilla¹, Alfonso Corrales¹, Ricardo Blanco¹, Jose Cifrian⁶, Miguel A Gonzalez-Gay⁷ and Raquel López-Mejías¹, ¹Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ²IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁷IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) constitutes one of the most critical comorbidities in autoimmune diseases (AD), particularly in rheumatoid arthritis (RA) and systemic sclerosis (SSc)…
Abstract Number: 0388 • ACR Convergence 2023
Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients
Victor Beltran¹, Iris Colunga², Dionicio A. Galarza-Delgado², José Ramón Azpiri-López², Jesus Alberto Cardenas-De la Garza³, Rosa Arvizu-Rivera⁴, Valeria Gonzalez-Gonzalez⁵ and Angel Arias Peralta⁶, ¹Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Mexico, ⁶Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) leading cause of death is cardiovascular (CV) disease. RA patients can develop silent myocardial tissue alterations, which result in changes in…
Abstract Number: 0404 • ACR Convergence 2023
Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
Carmen Roseman, Johan Karlsson Wallman, Jon Einarsson, Elisabeth Mogard, Elisabet Lindqvist, Meliha Kapetanovic and Tor Olofsson, Lund University and Skåne University Hospital, Lund, Sweden
Background/Purpose: Persisting pain with or without inflammation control is a common and debilitating symptom in rheumatoid arthritis (RA). Concerns have been raised that patients with…
Abstract Number: 0421 • ACR Convergence 2023
Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study
Gregory McDermott¹, Mary Jeffway¹, Thany Seyok¹, Harrison Zhang², Kumar Dahal¹, Dana Weisenfeld¹, Margaret Vella³, Tracy Johansson⁴, Gabriela Schmajuk⁵, Kaleb Michaud⁶, Cassandra Perry³, Susanne Churchill³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Harvard Medical School, Boston, MA, ⁴American College of Rheumatology, Atlanta, GA, ⁵UCSF / SFVA, San Francisco, CA, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although the modern RA treatment armamentarium has led to significant improvements in response rates and outcomes, some RA patients inadequately respond to multiple lines…
Abstract Number: 0438 • ACR Convergence 2023
Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review
Swetha Ann Alexander¹, Gordon Starkebaum², Diana Louden², Grant Hughes² and Namrata Singh³, ¹University of Utah Health, Salt Lake City, UT, ²University of Washington, Seattle, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Rheumatoid Arthritis (RA) patients have an increased risk of developing lymphoma compared to the general population. This increased risk is believed to be linked…
Abstract Number: 0455 • ACR Convergence 2023
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Kenneth Luu, Martin Dahl, Eric Hare, Cailin Sibley, Paul Lizzul and Bruce Randazzo, AnaptysBio, San Diego, CA
Background/Purpose: PD-1 pathway mutations increase human susceptibility to multiple autoimmune diseases, and insufficient PD-1 signaling can lead to dysregulated T cell responses. By targeting natural…
Abstract Number: 0734 • ACR Convergence 2023
Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases
Jun Inamo¹, Akari Suzuki², Mahoko Takahashi Ueda¹, Kensuke Yamaguchi¹, Hiroshi Nishida³, Katsuya Suzuki⁴, Yuko Kaneko⁵, Tsutomu Takeuchi⁶, Hiroaki Hatano⁷, Kazuyoshi Ishigaki⁸, Yasushi Ishihama³, Kazuhiko Yamamoto⁹ and Yuta Kochi¹, ¹Tokyo Medical and Dental University, Tokyo, Japan, ²RIKEN Center for Integrative Medical Science, Kanagawa, Japan, ³Kyoto University, Kyoto, Japan, ⁴Keio University, Shinjuku, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ⁸RIKEN, Tokyo, Japan, ⁹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Alternative splicing events play a critical role in the immune system1,2 and one of major causal mechanisms for complex traits including immune-mediated diseases (IMDs),…
Abstract Number: 0797 • ACR Convergence 2023
Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis
Agnieszka Lastowska¹, Charlotte E. van der Plas¹, Anders Nguyen¹, Symeon Kourmoulakis¹, Miriam Bollmann¹ and Mattias N.D Svensson², ¹Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid cells (ILCs) are innate counterparts to T-cells that, based on their functional phenotype, can be divided into three subpopulations called Group 1…
Abstract Number: 0866 • ACR Convergence 2023
A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies
André Tiaden¹, Simone Häner Massimi¹, Ulrich Walker², Diego Kyburz³ and Stavros Giaglis¹, ¹Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, ²Basel University Hospital, Basel, Switzerland, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Autoimmunity, trauma, or infection lead to devastating arthropathies, within enormous socioeconomic impact due to its high frequency and chronicity. The development of novel treatments…
Abstract Number: 0995 • ACR Convergence 2023
Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients
Mercedes Quinones¹, Sharon Dowell², Ilona Jileaeva³, Oshoze Kadiri³, Christopher Swearingen⁴ and Gail Kerr⁵, ¹Washington DC VA Medical Center, Bethesda, MD, ²NEA Baptist Memorial Hospital, Jonesboro, AR, ³Howard University, Washington, DC, ⁴Biosplice Therapeutics, Inc., San Diego, CA, ⁵Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Rheumatoid Arthritis (RA) data indicate a "window of opportunity" during which DMARD therapy is most effective in achieving early and sustained remission, hence expedited…
Abstract Number: 1071 • ACR Convergence 2023
No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs)
Madeline O'Sullivan¹, Grant Cannon¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel⁴, Jessica A Walsh⁵, Punyasha Roul⁶, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten⁴, ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴University of Utah, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) are used to treat multiple cancers with increasing frequency and have led to improved survival. However, there is limited data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].